Business & Finance
Drug-delivery company announces third-quarter net loss of $3 million
Published in Drug Week, November 11th, 2005
Durect's net loss for the 3 months ended September 30, 2005, was $3.0 million or 6 cents per share, compared to a net loss of $7.3 million or 14 cents per share for the same period in 2004. DURECT's results for the 3 months ended September 30, 2005, included noncash charges of $363,000 for the amortization of intangible assets and stock-based compensation, compared to $311,000 for the same period in 2004. Cash used in operating activities was $1.1 million for the 3 months ended September 30, 2005, compared to $4.4 million for the same period in 2004.
"We had a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-11-11)
More Articles from Drug Week
- Breast Cancer
Curcumin halts spread of breast cancer in mice - Cancer Therapy
Median survival improved by more than half in phase III metastatic melanoma trial of Oncophage - Drug Development
Phase II trial initiated for Cand5 in wet age-related macular degeneration - Renal Cell Carcinoma
Preliminary data shows renal cancer drug is safe and well tolerated - Systemic Lupus Erythematosus
LymphoStat-B shown to be safe, well-tolerated in patients with systemic lupus erythematosus - Addiction Medicine
Beta-carbolines block opiate withdrawal - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
